A Real-World Study of Polynucleotides HPT for Treating Periorbital Hyperpigmentation
Clinical, Cosmetic and Investigational Dermatology · 2026-05 · Volume 19 · 1-15
DOI: 10.2147/ccid.s605046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical, Cosmetic and Investigational Dermatology, 2026-05. Verfasst von Raquel Amado und 10 weiteren Autor:innen. Beteiligte Einrichtung: Skin and Medical Cosmetics, West Malling, UK. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Introduction and Purpose: Anatomic factors and age‑related changes in the midface, along with sun exposure, prolonged television viewing, anemia, and hormonal derangements, contribute to the development of periorbital hyperpigmentation, also known as dark circles. Intradermally injected PN HPT (Polynucleotides High Purification Technology) from trout gonads has an immediate volume-enhancing effect and a longer-term indirect restructuring action on dermal and subdermal tissues.
Methods
Open-label multinational observational cohort of 61 real-life multinational subjects of both genders and unskewed age distribution (mean 41.5 ± 10.5 years, range 20 to 67), with subjectively disturbing dark circles across all Huang subtypes. PN HPT hydrogel (7.5 mg/mL) in phosphate buffer was administered with needle or cannula at baseline (T0), after two to three weeks (second injection, T1), and two to three weeks after T1 (third injection, T2); usually 1 mL on the right periorbicular area and 1 mL on the left (lower doses allowed at the specialist's discretion). Post-treatment follow-up visits: Snapshot photographs were taken at 1 month (T3) and three months after the final T2 injection (T4) and digitally analyzed for color, pigmentation, and outcomes compared with T0 (primary endpoint). Every participating specialist and every treated subject also assessed hyperpigmentation and skin quality categories with GAIS-like scoring scales.
Results
Regarding the primary endpoint, the overall picture showed a generalized, highly significant shift toward less severe periorbital hyperpigmentation (p
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Skin and Medical Cosmetics, West Malling, UK.
- Dr Yusra Clinic, Liverpool, UK.
- Estederm Srl, Catania, Italy.
- B You Clinic, Milan, Italy.
- Da Vinci Clinic, Kuala Lumpur, Malaysia.
- Alainn Clinic, Petaling Jaya, Malaysia.
ORCID-Profile: Raquel Amado, Eliana Lanza, Pierfrancesco Bove, Nurul Ain Abdullah, Gonca Gökdemir, Nazli Caf, Ayse Serap Karadag, Carolina Prussia, Maurizio Cavallini
Zitieren
APA
Amado, R., Al-Mukhtar, Y., Lanza, E., Bove, P., Tan, T., Abdullah, N. A., Gökdemir, G., Caf, N., Karadag, A. S., Prussia, C., & Cavallini, M. (2026). A Real-World Study of Polynucleotides HPT for Treating Periorbital Hyperpigmentation. Clinical, Cosmetic and Investigational Dermatology, Volume 19, 1-15. https://doi.org/10.2147/ccid.s605046
Vancouver
Amado R, Al-Mukhtar Y, Lanza E, Bove P, Tan T, Abdullah NA, et al. A Real-World Study of Polynucleotides HPT for Treating Periorbital Hyperpigmentation. Clinical, Cosmetic and Investigational Dermatology. 2026;Volume 19:1-15. doi:10.2147/ccid.s605046
BibTeX
@article{Amado2026,
author = {Amado, Raquel and Al-Mukhtar, Yusra and Lanza, Eliana and Bove, Pierfrancesco and Tan, Tristan and Abdullah, Nurul Ain and Gökdemir, Gonca and Caf, Nazli and Karadag, Ayse Serap and Prussia, Carolina and Cavallini, Maurizio},
title = {A Real-World Study of Polynucleotides HPT for Treating Periorbital Hyperpigmentation},
journal = {Clinical, Cosmetic and Investigational Dermatology},
year = {2026},
volume = {Volume 19},
pages = {1--15},
doi = {10.2147/ccid.s605046}
}
EUVIMED